Trump Expresses Interest in Psychedelic Drug Ibogaine

In a press briefing, President Trump expressed interest in trying Ibogaine, a psychedelic drug, citing a 2024 Stanford University study that reported an 80 to 90% reduction in symptoms of depression and anxiety among special operation veterans with traumatic brain injuries who underwent the treatment. The study, which used Ibogaine, gained Trump's attention due to its potential benefits.